Treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70791258

Enrollment

Registered

2007-01-26

Start date

1999-07-06

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephropathy Urological and Genital Diseases Nephropathy

Interventions

The participants were randomised to treatment with Synacthen Depot or no specific treatment. Synacthen Depot is a depot preparation of a synthetic fragment of ACTH. The fragment consists of the first

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males and females 2. Age 18 to 90 3. Membranous nephropathy according to kidney biopsy 4. Proteinuria of the nephrotic range for at least six months 5. Treatment with a statin and an angiotensin converting enzyme inhibitor for at least three months 6. Urinary albumin excretion more than 3000 mg/24 hours 7. Serum albumin concentration less than 26 g/L

Exclusion criteria

Exclusion criteria: 1. Moderate or heavy tubulointerstitial changes in the kidney biopsy 2. A recognisable cause of the nephrotic syndrome 3. Previous immunosuppressive treatment for the membranous nephropathy 4. Allergy to Synacthen Depot 5. Severe psychiatric disease 6. Pregnancy 7. History of noncompliance

Design outcomes

Primary

Measure	Time frame
The primary outcomes were complete remissions and the combination of complete and partial remissions at the end of the treatment period (nine months after study start) and at the end of the follow-up period (21 months after study start). A complete remission was defined as urinary albumin excretion less than 200 mg/24 hours and a partial remission was defined as urinary albumin excretion less than 2000 mg/24 hours in combination with a reduction of at least 50%.	—

Measure

Time frame

The primary outcomes were complete remissions and the combination of complete and partial remissions at the end of the treatment period (nine months after study start) and at the end of the follow-up period (21 months after study start). A complete remission was defined as urinary albumin excretion less than 200 mg/24 hours and a partial remission was defined as urinary albumin excretion less than 2000 mg/24 hours in combination with a reduction of at least 50%.

—

Secondary

Measure	Time frame
The secondary outcomes were the changes at the end of the treatment period and the end of the follow-up period, as compared to baseline, in the serum concentrations of albumin, creatinine, apolipoprotein A1, apolipoprotein B and lipoprotein(a), the urinary excretion/24 hours of albumin, immunoglobulin G and protein HC, glomerular filtration rate and mean arterial pressure.	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026